Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD

Business Wire October 15, 2020

Sage Therapeutics Appoints Barry Greene to Board of Directors

Business Wire October 1, 2020

Sage Therapeutics' FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises

Business Wire September 10, 2020

Sage Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Business Wire September 1, 2020

Sage Therapeutics to Host Sage FutureCast Webcast

Business Wire August 20, 2020

Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

Business Wire August 10, 2020

Sage Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Business Wire July 30, 2020

Sage Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

Business Wire July 21, 2020

Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference

Business Wire June 1, 2020

Sage Therapeutics to Present at Bank of America Health Care Conference 2020

Business Wire May 8, 2020

Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

Business Wire May 7, 2020

Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

Business Wire April 16, 2020

Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline

Business Wire April 7, 2020

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 3, 2020

Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration

Business Wire March 18, 2020

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

GlobeNewswire March 11, 2020

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire March 4, 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud

GlobeNewswire February 27, 2020

Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress

Business Wire February 27, 2020

Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference

Business Wire February 24, 2020